首页> 外文期刊>The Journal of Urology >Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?
【24h】

Does neoadjuvant hormonal therapy improve urinary function when given to men with large prostates undergoing prostate brachytherapy?

机译:当对患有大前列腺的男性进行前列腺近距离放射治疗时,新辅助激素疗法会改善泌尿功能吗?

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: We evaluated the effect of neoadjuvant hormonal therapy on urinary function in men with a prostate volume of 50 cc or greater undergoing prostate brachytherapy. MATERIALS AND METHODS: A total of 395 men with 50 cc or greater glands were treated with 3 months of neoadjuvant hormonal therapy (204) or implantation alone (191). Urinary function was assessed by the International Prostate Symptom Score, the urinary retention incidence and subsequent transurethral prostate resection. RESULTS: Median patient age was 67 years and median followup was 6 years. Mean prostate volume in neoadjuvant hormonal therapy cases was 72.9 cc, which decreased to 54.3 cc after 3 months (p <0.001). Mean prostate volume in cases without hormonal therapy was 60.6 cc (p <0.001). Urinary retention occurred in 16 of 191 men (8.4%) without vs 25 of 204 (12.3%) with hormonal therapy (p = 0.207). The median duration of urinary retention was 42 days (range 2 to 243). There were no significant associations of urinary retention with prostate size, prostate or urethral dose, or pre-implantation International Prostate Symptom Score. Of patients without hormonal therapy retention occurred in 3 of 12 (25%) with a pre-implantation International Prostate Symptom Score of 15 or greater and in 13 of 168 (7.7%) with a score of less than 15 (OR 4.0, 95% CI 1-16, p = 0.04). In contrast, there was no difference in the retention rate in patients with hormonal therapy with an initial score of 15 or greater vs less than 15 (2 of 25 or 8% vs 11 of 102 or 10.8%, p = 0.614). Transurethral prostate resection was done in 11 of 191 men (5.8%) without vs 12 of 204 (5.9%) with hormonal therapy (p = 0.958). There was no difference in biochemical failure in the 2 groups. CONCLUSIONS: Neoadjuvant hormonal therapy has its greatest benefit in patients receiving brachytherapy who have a large prostate and an International Prostate Symptom Score of 15 or greater.
机译:目的:我们评估了前列腺癌体积大于等于50 cc的男性在接受前列腺近距离放射治疗时,新辅助激素治疗对泌尿功能的影响。材料与方法:总共395名50 cc或更大腺体的男性接受了3个月的新辅助激素治疗(204)或单独植入(191)。通过国际前列腺症状评分,尿retention留发生率和随后的经尿道前列腺切除术评估尿功能。结果:患者中位年龄为67岁,中位随访时间为6年。新辅助激素治疗病例的平均前列腺体积为72.9 cc,三个月后降至54.3 cc(p <0.001)。未进行激素治疗的患者平均前列腺体积为60.6 cc(p <0.001)。 191名男性中有16名患者发生尿(留(8.4%),而荷尔蒙治疗后有20名中的25名患者(12.3%)发生尿(留(p = 0.207)。尿retention留的中位持续时间为42天(范围2至243)。尿retention留与前列腺大小,前列腺或尿道剂量或植入前国际前列腺症状评分无显着相关性。在没有激素治疗的患者中,有12例中有3例(25%)发生了植入前的国际前列腺症状评分为15分或更高; 168例中有13例(7.7%)的评分小于15分(OR 4.0,95% CI 1-16,p = 0.04)。相比之下,荷尔蒙疗法的初始评分为15分或更高与小于15分的患者之间的保留率没有差异(25分或8%中的2分与102分或10.8%中的11分,p = 0.614)。经激素治疗的191例男性中有11例(5.8%)经尿道前列腺切除术,而204例中的12例(5.9%)进行了经尿道前列腺切除术(p = 0.958)。两组的生化失败率无差异。结论:新辅助激素治疗在接受近距离放射治疗的前列腺癌患者中最大获益,其国际前列腺症状评分为15或更高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号